MX362271B - Nueva forma cristalina de ciclosporina a, metodos de preparacion y metodos para su uso. - Google Patents

Nueva forma cristalina de ciclosporina a, metodos de preparacion y metodos para su uso.

Info

Publication number
MX362271B
MX362271B MX2013013855A MX2013013855A MX362271B MX 362271 B MX362271 B MX 362271B MX 2013013855 A MX2013013855 A MX 2013013855A MX 2013013855 A MX2013013855 A MX 2013013855A MX 362271 B MX362271 B MX 362271B
Authority
MX
Mexico
Prior art keywords
methods
cyclosporine
preparation
crystalline form
crystalline forms
Prior art date
Application number
MX2013013855A
Other languages
English (en)
Spanish (es)
Other versions
MX2013013855A (es
Inventor
Karami Kiomars
s graham Richard
V Gore Anuradha
W Smith Scott
Wu Ke
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46178866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX362271(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2013013855A publication Critical patent/MX2013013855A/es
Publication of MX362271B publication Critical patent/MX362271B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • C07K7/645Cyclosporins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/30Extraction; Separation; Purification by precipitation
    • C07K1/306Extraction; Separation; Purification by precipitation by crystallization
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
MX2013013855A 2011-05-27 2012-05-25 Nueva forma cristalina de ciclosporina a, metodos de preparacion y metodos para su uso. MX362271B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161490887P 2011-05-27 2011-05-27
PCT/US2012/039611 WO2012166610A1 (en) 2011-05-27 2012-05-25 A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof

Publications (2)

Publication Number Publication Date
MX2013013855A MX2013013855A (es) 2014-02-17
MX362271B true MX362271B (es) 2019-01-10

Family

ID=46178866

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013855A MX362271B (es) 2011-05-27 2012-05-25 Nueva forma cristalina de ciclosporina a, metodos de preparacion y metodos para su uso.

Country Status (19)

Country Link
US (4) US8772245B2 (https=)
EP (2) EP2714720B1 (https=)
JP (1) JP6163482B2 (https=)
KR (1) KR102079402B1 (https=)
CN (1) CN103649108B (https=)
AR (1) AR086586A1 (https=)
AU (4) AU2012262513B2 (https=)
BR (1) BR112013030554B1 (https=)
CA (1) CA2836946C (https=)
CL (1) CL2013003400A1 (https=)
IL (2) IL229475A0 (https=)
MX (1) MX362271B (https=)
MY (1) MY180581A (https=)
RU (1) RU2602062C2 (https=)
SG (1) SG10201607344UA (https=)
TW (1) TWI554522B (https=)
UA (1) UA113627C2 (https=)
WO (1) WO2012166610A1 (https=)
ZA (1) ZA201308665B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3701939A1 (en) * 2011-11-15 2020-09-02 Allergan, Inc. Suspensions of cyclosporin a form 2
WO2013074610A1 (en) 2011-11-15 2013-05-23 Allergan, Inc. Sustained action formulation of cyclosporin form 2
BR112014011768A2 (pt) * 2011-11-15 2017-05-09 Allergan Inc forma 2 de ciclosporina a e método de produção da mesma
US20130123194A1 (en) * 2011-11-15 2013-05-16 Allergan, Inc. Autoclavable suspensions of cyclosporin a form 2
JP2015519368A (ja) 2012-06-01 2015-07-09 アラーガン インコーポレイテッドAllergan,Incorporated シクロスポリンa類似体
GB201222455D0 (en) * 2012-12-13 2013-01-30 Perioc Ltd Novel pharmaceutical formulations and their use in the treatment of periodontaldisease
US10524661B2 (en) * 2013-06-12 2020-01-07 Proactive Live, Inc. Sleep monitoring and stimulation
RU2713953C2 (ru) 2014-07-18 2020-02-11 Аллерган, Инк. Суспензионные составы циклоспорина а для субконъюнктивального и периокулярного введения
US9914755B2 (en) 2015-01-08 2018-03-13 Allergan, Inc. Cyclosporin derivatives wherein the MeBmt sidechain has been cyclized
US10443292B2 (en) * 2016-04-25 2019-10-15 Magna Closures, Inc. Non-contact obstacle detection system for motor vehicles
RU2766160C2 (ru) 2017-05-17 2022-02-08 Юю Фарма, Инк. Новый пептид и фармацевтический состав для лечения глазного заболевания, содержащий пептид в качестве активного фармацевтического ингредиента
US11613558B2 (en) 2018-11-14 2023-03-28 Yuyu Pharma, Inc. Peptides and pharmaceutical compositions for treating eye diseases
MX2024002234A (es) * 2021-08-20 2024-04-17 Sun Pharmaceutical Ind Ltd Formulación oftalmológica de ciclosporina estable y proceso de fabricación de esta.
TW202430537A (zh) 2022-10-20 2024-08-01 日商中外製藥股份有限公司 環狀胜肽的結晶的製造方法
WO2024195801A1 (ja) 2023-03-20 2024-09-26 中外製薬株式会社 環状ペプチドの共結晶の製造方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU203564B (en) * 1987-12-21 1991-08-28 Sandoz Ag Process for producing new orthorombos cyclosporin without solvatation
GB9105705D0 (en) * 1991-03-18 1991-05-01 Sandoz Ltd Improvements in or relating to organic compounds
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
US6254860B1 (en) * 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
US6656504B1 (en) * 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
RU2009144186A (ru) 2007-05-04 2011-06-10 Аллерган, Инк. (Us) Применение циклоспоринов при лечении пациентов с интраокулярными линзами
US20090286718A1 (en) * 2008-01-04 2009-11-19 Sirion Therapeutics, Inc. Stable Aqueous Cyclosporin Compositions

Also Published As

Publication number Publication date
KR20140047054A (ko) 2014-04-21
US9206228B2 (en) 2015-12-08
AU2012262513B2 (en) 2016-03-17
US20210269484A1 (en) 2021-09-02
UA113627C2 (xx) 2017-02-27
US20160083432A1 (en) 2016-03-24
WO2012166610A1 (en) 2012-12-06
EP3521302A1 (en) 2019-08-07
SG10201607344UA (en) 2016-10-28
CA2836946A1 (en) 2012-12-06
CL2013003400A1 (es) 2014-08-18
CN103649108A (zh) 2014-03-19
JP2014515372A (ja) 2014-06-30
EP2714720A1 (en) 2014-04-09
RU2602062C2 (ru) 2016-11-10
TW201311730A (zh) 2013-03-16
AU2016203990A1 (en) 2016-06-30
BR112013030554B1 (pt) 2020-12-15
AU2012262513A1 (en) 2013-12-12
AU2019204192B2 (en) 2021-02-04
MY180581A (en) 2020-12-02
MX2013013855A (es) 2014-02-17
BR112013030554A2 (pt) 2016-09-06
ZA201308665B (en) 2014-07-30
JP6163482B2 (ja) 2017-07-12
KR102079402B1 (ko) 2020-02-19
NZ719272A (en) 2017-10-27
CA2836946C (en) 2017-08-01
AR086586A1 (es) 2014-01-08
TWI554522B (zh) 2016-10-21
US20130023482A1 (en) 2013-01-24
EP2714720B1 (en) 2018-12-26
IL229475A0 (en) 2014-01-30
US20140315827A1 (en) 2014-10-23
RU2013155033A (ru) 2015-07-20
IL290158A (en) 2022-03-01
US8772245B2 (en) 2014-07-08
AU2017265008A1 (en) 2017-12-07
AU2019204192A1 (en) 2019-07-04
NZ618213A (en) 2016-05-27
CN103649108B (zh) 2017-03-29

Similar Documents

Publication Publication Date Title
MX362271B (es) Nueva forma cristalina de ciclosporina a, metodos de preparacion y metodos para su uso.
IL274469A (en) Compositions, uses and methods for the treatment of metabolic disorders and diseases
EA033455B1 (ru) Кристаллические формы замещенных 5-фтор-1h-пиразолопиридинов, способы их получения, их применение для получения лекарственного средства, лекарственное средство и способ лечения на их основе
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
IL245792A0 (en) Diaminocarboxamide and diaminocarbonitrile converted pyrimidines, their compositions and methods of treatment
PH12014500904B1 (en) Antibody formulations and methods
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
WO2013177133A3 (en) Generation of human ips cells by a synthetic self- replicative rna
EP2665696A4 (en) PROCESS FOR THE PREPARATION OF 2,3,3,3-TETRAFLUOR-2-PROPENE
WO2012106393A3 (en) Withanolide isolated from physalis longifolia and analogs and methods of use thereof
SG10202010665YA (en) Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders
WO2012129341A3 (en) Disease detection in plants
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
WO2013034979A3 (en) Crystalline forms of cabazitaxel
IL232710A0 (en) l-serine preparations, methods and uses for the treatment of neurodegenerative diseases and disorders
ZA201403430B (en) 4-pregenen- 11ss -17 - 21-triols-3, 20- dione derivatives for the treatment of ocular conditions
MX370253B (es) Composiciones de compuestos de jasmonato y métodos de uso de las mismas.
UA108878C2 (ru) Ингибиторы протеинтирозинкиназной активности
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
WO2012112674A3 (en) Compounds and methods of use thereof for treating neurodegenerative disorders
MX2013007567A (es) Procedimiento para preparar poliestereteroles.
IN2014DN06964A (https=)
MX2013015347A (es) Terapia direccionada al receptor del factor de crecimiento epidermico (egfr).
HK1201067A1 (en) Sialic acid analogs
WO2013155465A8 (en) Substituted xanthine derivatives

Legal Events

Date Code Title Description
FG Grant or registration